| Teriparatide or alendronate in glucocorticoid-induced osteoporosis KG Saag, E Shane, S Boonen, F Marín, DW Donley, KA Taylor, GP Dalsky, ... New England Journal of Medicine 357 (20), 2028-2039, 2007 | 1067 | 2007 |
| Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised … DL Kendler, F Marin, CAF Zerbini, LA Russo, SL Greenspan, V Zikan, ... The Lancet 391 (10117), 230-240, 2018 | 503 | 2018 |
| Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment BM Obermayer‐Pietsch, F Marin, EV McCloskey, P Hadji, J Farrerons, ... Journal of bone and mineral research 23 (10), 1591-1600, 2008 | 303 | 2008 |
| Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis S Boonen, F Marin, B Obermayer-Pietsch, ME Simoes, C Barker, ... The Journal of Clinical Endocrinology & Metabolism 93 (3), 852-860, 2008 | 259 | 2008 |
| Change in bone density and reduction in fracture risk: a meta‐regression of published trials ML Bouxsein, R Eastell, LY Lui, LA Wu, AE de Papp, A Grauer, F Marin, ... Journal of Bone and Mineral Research 34 (4), 632-642, 2019 | 248 | 2019 |
| Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS) R Eastell, T Nickelsen, F Marin, C Barker, P Hadji, J Farrerons, M Audran, ... Journal of bone and mineral research 24 (4), 726-736, 2009 | 223 | 2009 |
| Relationship between bone quantitative ultrasound and fractures: A meta‐analysis F Marín, J González‐Macías, A Díez‐Pérez, S Palma, ... Journal of bone and mineral research 21 (7), 1126-1135, 2006 | 207 | 2006 |
| Teriparatide for osteoporosis: importance of the full course R Lindsay, JH Krege, F Marin, L Jin, JJ Stepan Osteoporosis international 27, 2395-2410, 2016 | 200 | 2016 |
| Comparative effects of teriparatide and risedronate in glucocorticoid‐induced osteoporosis in men: 18‐month results of the EuroGIOPs trial CC Glüer, F Marin, JD Ringe, F Hawkins, R Möricke, N Papaioannu, ... Journal of bone and mineral research 28 (6), 1355-1368, 2013 | 187 | 2013 |
| Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis RR Recker, F Marin, S Ish‐Shalom, R Möricke, F Hawkins, G Kapetanos, ... Journal of Bone and Mineral Research 24 (8), 1358-1368, 2009 | 179 | 2009 |
| Monitoring teriparatide‐associated changes in vertebral microstructure by high‐resolution CT in vivo: results from the EUROFORS study C Graeff, W Timm, TN Nickelsen, J Farrerons, F Marín, C Barker, CC Glüer Journal of Bone and Mineral Research 22 (9), 1426-1433, 2007 | 173 | 2007 |
| Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective S Boonen, F Marin, D Mellstrom, L Xie, D Desaiah, JH Krege, CJ Rosen Journal of the American Geriatrics Society 54 (5), 782-789, 2006 | 155 | 2006 |
| Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort J González-Macías, F Marin, J Vila, A Díez-Pérez Bone 50 (1), 373-377, 2012 | 150 | 2012 |
| Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status BL Langdahl, F Marin, E Shane, H Dobnig, JR Zanchetta, M Maricic, ... Osteoporosis International 20, 2095-2104, 2009 | 147 | 2009 |
| High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA … C Graeff, F Marin, H Petto, O Kayser, A Reisinger, J Peña, P Zysset, ... Bone 52 (2), 568-577, 2013 | 144 | 2013 |
| Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized … C Turbí, G Herrero-Beaumont, JC Acebes, A Torrijos, J Graña, R Miguélez, ... Clinical therapeutics 26 (2), 245-256, 2004 | 130 | 2004 |
| Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results … J Borggrefe, C Graeff, TN Nickelsen, F Marin, CC Glüer Journal of Bone and Mineral Research 25 (3), 472-481, 2010 | 125 | 2010 |
| Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple … DM Black, DC Bauer, E Vittinghoff, LY Lui, A Grauer, F Marin, S Khosla, ... The lancet Diabetes & endocrinology 8 (8), 672-682, 2020 | 121 | 2020 |
| Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational … BL Langdahl, G Rajzbaum, F Jakob, D Karras, Ö Ljunggren, WF Lems, ... Calcified tissue international 85, 484-493, 2009 | 120 | 2009 |
| Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound A Diez-Perez, J Gonzalez-Macias, F Marin, M Abizanda, R Alvarez, ... Osteoporosis International 18, 629-639, 2007 | 108 | 2007 |
Adolfo Diez PerezVerified email at parcdesalutmar.cat
